For CEO Matthew Ko, DeepScribe's partnership with Flatiron Health represents more than just business growth – it's the fulfillment of a personal mission. In this interview, Ko reveals how cancer touched his own family, inspiring DeepScribe's founding commitment to oncology and its unique approach to specialty-specific AI.
The partnership, which brings DeepScribe's ambient AI documentation to Flatiron's OncoEMR® platform, will serve more than 4,200 providers across 800+ community-based cancer centers nationwide. Ko explains that oncology documentation presents distinct challenges that require specialized AI models, challenges that DeepScribe has been addressing since inception.
Transcript:
The traction that we've made in oncology and now with our partnership with Flatiron, it means a lot to me. It means that we're really delivering on our promise, and this world is starting to notice. We also are very, very particular about building custom models for specific specialties and for specific providers. For those of you that don't know, we started the company oncology. My mom had breast cancer, and my cofounder's dad is an oncologist through that experience and through my cofounder's father.
That's really how we came up with this idea of DeepScribe to begin with. If you ever spend time, reading notes, for cancer visits, what you'll find is that they're really different from a lot of the other types of notes that you see in medicine. To design a workflow and design a product, design a technology, that is able to accommodate for the nuances of cancer care has been a challenge, but it's also been rewarding. And one of those rewards is this partnership with Flatiron where they, really acknowledged all the work that we've done and, you know, chose us as as their partner.
text
